Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05080946 · ClinicalTrials.gov registry record · Early Phase 1

Using Aspirin to Improve Immunological Features of Ovarian Tumors

A Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Recruiting
Registry status
Early Phase 1
Development phase
100
Enrollment target
4
Study locations

NCT05080946 is a Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 100 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05080946, a Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

RECRUITING
Registry status
Early Phase 1
Development phase
100 participants
Enrollment target
4
Study locations

Study Summary

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

Interventions

  • DRUG Placebo
  • DRUG Aspirin 325mg

Study Locations (4)

Virginia

  • University of Virginia Comprehensive Cancer Center - Charlottesville
  • Inova Schar Cancer Institute - Fairfax

Florida

  • Moffitt Cancer Center - Tampa

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-11-02
Est. Completion 2026-12
Phase Early Phase 1

What the Registry Record Tells You About NCT05080946

The ClinicalTrials.gov registry entry for NCT05080946 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (86% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05080946 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Virginia, Florida, Oregon.

Frequently Asked Questions

What is clinical trial NCT05080946 about?

NCT05080946 is a clinical study titled "Using Aspirin to Improve Immunological Features of Ovarian Tumors". The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

What is the current status of trial NCT05080946?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2021-11-02. Estimated completion is 2026-12.

What conditions does trial NCT05080946 study?

This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.

What interventions are being tested in trial NCT05080946?

The interventions under investigation include: Placebo (DRUG), Aspirin 325mg (DRUG).

Who is sponsoring clinical trial NCT05080946?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05080946 being conducted?

This trial has 4 study locations across Florida, Oregon, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.